Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

[Tester av enhet som inte är godkänd eller godkänd av U.S. FDA] (STANCE)

24 september 2026 uppdaterad av: C. R. Bard

Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is designed using an adaptive approach. The number of the treated breasts will range between 250 and 530.

Studieöversikt

Detaljerad beskrivning

Capsular contracture is the number one complication leading to revision surgery after breast augmentation(2-4) which has been commonly cited as impacting 10 to 20% of all breast augmentation patients.(5-10) A prospective, randomized controlled study of patients presenting with Baker grade III or IV capsular contracture will be undertaken to investigate the ability of P4HB (specifically GalaFLEX LITE™ Scaffold) to reduce the recurrence of clinically significant CC and/or malposition requiring surgical correction. The primary endpoint is a composite of capsular contracture recurrence and/or breast implant malposition recommended for surgery OR breast infections requiring oral or IV antibiotic treatment within 90 days of surgery and/or peri-implant fluid collection needing a drainage procedure within 10-90 days of surgery.

Studietyp

Interventionell

Inskrivning (Beräknad)

250

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Arizona
      • Scottsdale, Arizona, Förenta staterna, 82521
        • Rekrytering
        • Defyne MD
        • Huvudutredare:
          • Oren Tessler
        • Kontakt:
    • California
      • Beverly Hills, California, Förenta staterna, 90210
        • Rekrytering
        • The Practice Plastic Surgery
        • Huvudutredare:
          • Kelly Killeen, MD, FACS
        • Kontakt:
      • Huntington Beach, California, Förenta staterna, 92647
        • Rekrytering
        • California Aesthetic Center
        • Huvudutredare:
          • Steve Vu
        • Kontakt:
      • Newport Beach, California, Förenta staterna, 92660
        • Rekrytering
        • Newport Plastic and Reconstructive Surgery Associates
        • Huvudutredare:
          • Hisham Seify
        • Kontakt:
      • Newport Beach, California, Förenta staterna, 92660
        • Rekrytering
        • Donald S Mowlds, MD A Professional Corporation
        • Kontakt:
        • Huvudutredare:
          • Donald S Mowlds, MD
      • Pasadena, California, Förenta staterna, 91101
        • Rekrytering
        • Stewart Wang MD Inc.
        • Kontakt:
        • Huvudutredare:
          • Stewart Wang
      • San Diego, California, Förenta staterna, 92121
        • Indragen
        • Tim Sayed MD
      • San Diego, California, Förenta staterna, 92107
        • Rekrytering
        • Charlie Chen MD., Corp
        • Huvudutredare:
          • Charlie Chen
        • Kontakt:
    • Colorado
      • Lone Tree, Colorado, Förenta staterna, 80124
        • Rekrytering
        • Beauty by Buford
        • Huvudutredare:
          • Gregory Buford
        • Kontakt:
    • Florida
      • Boca Raton, Florida, Förenta staterna, 33431
        • Indragen
        • Sanctuary Plastic Surgery
      • Miami, Florida, Förenta staterna, 33134
        • Rekrytering
        • Careaga Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Daniel Careaga, MD
      • Orlando, Florida, Förenta staterna, 32819
        • Rekrytering
        • Aesthetic Enhancements Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Armando Soto
      • Orlando, Florida, Förenta staterna, 32827
      • St. Petersburg, Florida, Förenta staterna, 33710
        • Rekrytering
        • Billington Plastic Surgery
        • Huvudutredare:
          • Alicia Billington, MD
        • Kontakt:
      • Tampa, Florida, Förenta staterna, 33606
        • Rekrytering
        • VIVIFY Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Dallas Buchanan, MD
    • Georgia
      • Alpharetta, Georgia, Förenta staterna, 30005
        • Rekrytering
        • The Graivier Center
        • Kontakt:
        • Huvudutredare:
          • David Hill, MD
      • Atlanta, Georgia, Förenta staterna, 30328
        • Rekrytering
        • Monarch Plastic Surgery and Skin Renewal Center
        • Kontakt:
        • Huvudutredare:
          • Carmen Kavali
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60642
        • Rekrytering
        • Iteld Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Lawrence Iteld, MD
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46290
        • Rekrytering
        • Meridian Plastic Surgery Center
        • Kontakt:
        • Huvudutredare:
          • Bruce W Van Natta
    • Louisiana
      • Mandeville, Louisiana, Förenta staterna, 70448
        • Rekrytering
        • Northshore Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Jeffrey Claiborne
    • Missouri
      • St Louis, Missouri, Förenta staterna, 63110
        • Rekrytering
        • The Washington University
        • Huvudutredare:
          • Justin Sacks
        • Kontakt:
    • Nevada
      • Reno, Nevada, Förenta staterna, 89511
        • Rekrytering
        • Reno Tahoe Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Tiffany McCormack, MD
    • New Jersey
      • West Long Branch, New Jersey, Förenta staterna, 07764
        • Rekrytering
        • VIP Plastic Surgery
        • Huvudutredare:
          • Rahul Vemula
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10021
        • Rekrytering
        • Luxurgery
        • Kontakt:
        • Huvudutredare:
          • Sachin Shridharani, MD
      • New York, New York, Förenta staterna, 10036
        • Rekrytering
        • Plastic Surgery Institute of New York
        • Kontakt:
        • Huvudutredare:
          • Matthew DelMauro, MD
        • Underutredare:
          • Adam Schaffner, MD
    • North Carolina
      • Huntersville, North Carolina, Förenta staterna, 28078
        • Rekrytering
        • H/K/B Surgery
        • Huvudutredare:
          • Bill Kortesis, MD, FACS
        • Kontakt:
    • Oklahoma
      • Tulsa, Oklahoma, Förenta staterna, 74137
        • Indragen
        • Essential Medical Research
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • Rekrytering
        • Pittsburgh Center for Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Armando Davila, MD
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Rekrytering
        • The Plastic Surgery Center of Nashville With HKB
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Mary Gingrass, MD
        • Underutredare:
          • Melinda Haws
    • Texas
      • Dallas, Texas, Förenta staterna, 75219
        • Rekrytering
        • Farah Naz Khan
        • Kontakt:
        • Huvudutredare:
          • Farah Khan
      • El Paso, Texas, Förenta staterna, 79936
      • Houston, Texas, Förenta staterna, 77024
      • San Antonio, Texas, Förenta staterna, 78257
        • Rekrytering
        • Hill Country Plastic Surgery
        • Kontakt:
        • Huvudutredare:
          • Amita Shah
        • Underutredare:
          • Scott Farber
      • San Antonio, Texas, Förenta staterna, 78258
        • Avslutad
        • Next Stage Clinical Research
    • Utah
      • Draper, Utah, Förenta staterna, 84020
        • Rekrytering
        • The Plastics Clinic
        • Huvudutredare:
          • Jerry Chidester
        • Kontakt:
    • Washington
      • Seattle, Washington, Förenta staterna, 98005
        • Rekrytering
        • Athenix Advanced Plastic Surgery & Aesthetic Center
        • Kontakt:
        • Huvudutredare:
          • Gavin Dry
      • Vancouver, Washington, Förenta staterna, 98660

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

22 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  1. Genetically female ≥22 and ≤70 years of age;
  2. Breast augmentation subject with capsular contracture (Baker grade III or IV);
  3. Desires a new silicone implant with no more than a ± 150cc volume change in implant size;
  4. Planned revision approach via inframammary fold (IMF) incision;
  5. Willing and able to comply with the study procedures including the 2-year follow-up visit;
  6. Can complete all required study visits as scheduled (i.e., physically attend);
  7. Has reviewed and completed an FDA required Breast Implant Patient Decision Checklist (e.g., implant-specific provided by the manufacturer);
  8. Has compatible smart technology that can be used for downloading/using the electronic patient diary; and,
  9. Provision of signed and dated informed consent form.

Exclusion Criteria:

  1. BMI <18 or >35
  2. Existing and/or replacement implant size > 800 cc
  3. Has an extra-capsular silicone breast implant rupture where silicone gel has leaked outside of the capsule) in breast(s) intended for treatment
  4. Has prior use of a matrix (synthetic or biologic) in the breast(s) intended for treatment
  5. Abnormal breast findings on imaging within 1-year prior to randomization that have not been determined to be benign
  6. Subject reported current, or prior history of, Systemic Symptoms Associated with Breast Implants (SSBI - formerly referred to as BII (Breast Implant Illness))
  7. Infection present in the study breast(s) (day of index procedure (surgery) exclusions)
  8. Current or recent breastfeeding (within 3-months of enrollment) or history of mastitis within the 6-months prior to enrollment
  9. Prior or current diagnosis of breast cancer
  10. Has a mass that was palpated and has not been determined benign via acceptable imaging (MRI) or biopsy results
  11. Has undergone prior chest radiation treatment
  12. Has received chemotherapy within the last 12 months
  13. Current or recent (within 1-year of enrollment) alcohol/substance abuse
  14. Current or recent (within 4-weeks of enrollment) nicotine user (includes cigarettes, vaping, patches, gum, etc.)
  15. History of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIAALCL) or Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC)
  16. Planned use of any other matrix (synthetic, biosynthetic, or biological) in the study breast(s) other than the GalaFLEX LITE™ Scaffold used to fully wrap the implant
  17. Planned (within the 2-year follow-up time period) use of medical (e.g. montelukast/Singulair; zafirlukast/Accolate), physical (e.g. massage), or device assisted (e.g. mechanical/thermal ultrasound) tools to manage the breast capsule(s)
  18. Any medical condition that, in the opinion of the investigator, may be associated with unduly high risk of intra- or post-operative complications (e.g., insulin dependent diabetes, autoimmune disease, connective tissue disorder, chronic lung or severe cardiovascular disease)
  19. Concurrent or planned use (within the 2-year follow-up time period) of autologous fat transfer in the study breast(s)
  20. Planned (within the 2-year follow-up time period) elective cosmetic surgery on the study breast(s) (e.g., staged mastopexy; revision for implant size change)
  21. Currently enrolled or has plans to enroll in another interventional clinical study that would interfere with this study
  22. Is pregnant or plans to become pregnant during the study period
  23. Known allergy to tetracycline hydrochloride and/or kanamycin sulfate
  24. Any condition that, in the Investigator's opinion, would preclude the use of the study device, interfere with the evaluation of the device or breast related outcomes
  25. Subject will not remain under the care of the investigator for all breast related plastic surgery procedures while enrolled in the study
  26. Actively using immunosuppressants such as oral steroids or biological therapies (inhalers or topical steroids are permitted)
  27. Confirmed diagnosis of the following rheumatic diseases or syndromes: systemic lupus erythematosus, Sjorgren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
  28. Has, in the investigator's opinion, a mental illness or disability that would preclude their participation in the study
  29. Subject has an implant that was never commercially available in the United States
  30. Has been implanted with any silicone implant other than breast implants
  31. Is taking any drugs that would interfere with blood clotting or might result in elevated risk of significant postoperative complications (e.g., anticoagulants or antiplatelet medications such as Xarelto, Aspirin, or Eliquis. NSAIDs such as Celebrex, Ibuprofen, Meloxicam are not exclusionary).
  32. Works for Sponsor or any of their subsidiaries, the study surgeon, or is helping to conduct the study or are directly related to anyone that works for BD or any of their subsidiaries or the study surgeons
  33. Subjects planning to undergo significant weight loss utilizing surgical intervention or prescribed medication(s) (e.g., gastric bypass; gastric sleeve; GLP1 agonists). Subjects with stable weight after previous surgery or current GLP-1 agonists use are not excluded.

Day of Index Procedure (Surgery) Exclusion Criteria

  1. Has an extra-capsular rupture (breast implant silicone gel has leaked outside of the capsule) in breast(s) intended for treatment
  2. Suspicions of cancer from intraoperative capsule appearance such as capsule masses (based on surgical opinion/visual findings; does not require definitive pathology) inclusive of both BIA-ALCL and BIA-SCC; or,
  3. Presence of a systemic infection, infection at the surgical site, or infection anywhere in the body at the time of surgery.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: GalaFlex Light Scaffold

Surgery performed with GalaFlex Lite Scaffold.

Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue

Aktiv komparator: Standard Surgery

Surgery performed using standard surgical procedures with no scaffold.

Surgery performed without the use of a scaffold

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Effectiveness of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket
Tidsram: 24-months after index surgery

Composite of Recurrent Capsular Contracture Baker grade III/IV and/or breast implant malposition

24-months after index surgery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient quality of life and satisfaction (12-month)
Tidsram: 12-months after index surgery

Select Breast-Q© modules (standardized patient survey) for the treated breast(s): psychosocial wellbeing; sexual wellbeing; satisfaction with breasts; and physical wellbeing - chest

12-months after index surgery
Patient quality of life and satisfaction
Tidsram: 24-months after index surgery

Select Breast-Q© modules (standardized patient survey) for the treated breast(s): psychosocial wellbeing; sexual wellbeing; satisfaction with breasts; and physical wellbeing - chest

24-months after index surgery
Safety of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket, reduction of capsular contracture recurrence, and/or malposition
Tidsram: 90 days

The occurrence of:

  • Breast fluid collection requiring a drainage procedure at any time, or after drain removal if one is used, within 90 days of surgery
  • Breast infection requiring oral (PO) or intravenous (IV) antibiotics related to the contracture revision surgery within 90 days of surgery
90 days

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Device or procedure related adverse events
Tidsram: 24-months after index surgery

Select adverse events including: breast infection requiring PO or IV antibiotics related to the revision surgery; breast fluid collection requiring a drainage procedure; breast implant loss; any unscheduled/unanticipated breast reoperation; breast implant malposition recommended for surgery; skin necrosis; wound dehiscence; any seroma within 90 days of surgery; any hematoma within 90 days of surgery; capsular contracture Baker Grade >1; and red breast syndrome

24-months after index surgery

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 december 2024

Primärt slutförande (Beräknad)

1 februari 2029

Avslutad studie (Beräknad)

1 februari 2029

Studieregistreringsdatum

Först inskickad

6 juli 2023

Först inskickad som uppfyllde QC-kriterierna

6 juli 2023

Första postat (Faktisk)

14 juli 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • DVL-BR-001

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera